Mission Wealth Management LP Boosts Stake in GSK plc (NYSE:GSK)

Mission Wealth Management LP raised its holdings in GSK plc (NYSE:GSK) by 17.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 10,518 shares of the pharmaceutical company’s stock after purchasing an additional 1,555 shares during the period. Mission Wealth Management LP’s holdings in GSK were worth $356,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. purchased a new stake in GSK in the fourth quarter valued at $1,136,000. Jones Financial Companies Lllp raised its holdings in shares of GSK by 28.8% in the 4th quarter. Jones Financial Companies Lllp now owns 72,435 shares of the pharmaceutical company’s stock valued at $2,450,000 after buying an additional 16,185 shares during the period. SRS Capital Advisors Inc. raised its holdings in shares of GSK by 51.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,414 shares of the pharmaceutical company’s stock valued at $48,000 after buying an additional 480 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of GSK by 65.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 11,946 shares of the pharmaceutical company’s stock valued at $402,000 after buying an additional 4,746 shares during the period. Finally, Cape Investment Advisory Inc. raised its holdings in shares of GSK by 12.8% in the 4th quarter. Cape Investment Advisory Inc. now owns 7,184 shares of the pharmaceutical company’s stock valued at $243,000 after buying an additional 818 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on GSK. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Morgan Stanley began coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Trading Up 0.9 %

GSK opened at $38.79 on Thursday. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.92. The stock has a market capitalization of $80.38 billion, a price-to-earnings ratio of 24.39, a PEG ratio of 1.12 and a beta of 0.58. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The business has a fifty day moving average price of $35.25 and a 200 day moving average price of $37.20.

GSK (NYSE:GSK) last released its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Sell-side analysts expect that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.05%. The ex-dividend date is Friday, February 21st. GSK’s dividend payout ratio is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.